BIXINK "Reimbursement for Nerlynx anticipated next year" : BIXINK

Notifications

Back

Notification settings

Back

Post notifications

Be notified when someone leaves a comment or a reply to your post or comment.

Updates and news

Stay ahead of important updates and news from the site.

Alarm
My account Sign out

Vision
Mission
Greeting
Our people

CANCER THERAPEUTICS

Nerlynx®
MUCOSAMIN®
Oncology Portal

DIGITAL THERAPEUTICS

OC Free ®
WEPEACH ®
attune™
SparkRx™

Press Release
IR

Location
Inquiry

한국어
English

CANCER THERAPEUTICS

DIGITAL THERAPEUTICS

Vision
Mission
Greeting
Our people

CANCER THERAPEUTICS

Nerlynx®
MUCOSAMIN®
Oncology Portal

DIGITAL THERAPEUTICS

OC Free ®
WEPEACH ®
attune™
SparkRx™

Press Release
IR

Location
Inquiry

한국어
English

한국어
English

MEDIA

Press Release
IR

Press Release

BIXINK "Reimbursement for Nerlynx anticipated next year"

9 Feb 2022

Views 498

https://www.hankyung.com/it/article/202201199921i

0

BIXINK signed contract with Taiwanese pharma company for Mucosamin, product for oral mucositis management in cancer patients BIXINK obtains market authorization of Nerlynx in Korea for early breast cancer

List

Copyright 2021 - BIXINK │ Terms of Use

Contact │ Privacy

6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258,

Republic of Korea

Copyright 2021 - BIXINK │ Terms of Use │ Contact │ Privacy

6F, 561 Nonhyeon-ro, Gangnam-gu, Seoul 06125, Republic of Korea